“Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study”, FE, vol. 18, no. 1, Oct. 2017, doi: 10.7175/fe.v18i1.1332.